Evaluation of Thymoglobulin Induction and Reduced Doses of Calcineurin Inhibitors on Liver Transplant Rejection

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Liver DysfunctionRejection, TransplantTransplantation, Liver
Interventions
BIOLOGICAL

Thymoglobulin

Antibody inductions with tacrolimus and corticosteroid sparing maintenance therapy

DRUG

Corticosteroid

For a minimum of 3 months

DRUG

Tacrolimus

Between Day 3 the last dose of Thymoglobulin

DRUG

Mycophenolate Mofetil

for at least 1 month posttransplant

Trial Locations (16)

10029

Mount Sinai Medical Center, New York

23298

VCU Medical Center, Richmond

32224

Mayo Clinic Jacksonville, Jacksonville

33136

University of Miami, Miami

35294

University of Alabama, Birmingham, Birmingham

45267

University of Cincinnati Medical Center, Cincinnati

55455

Fairview University Medical Center, Minneapolis

63110

Washington University Medical Center, St Louis

68198

University of Nebraska, Omaha

75246

Baylor University Medical Center, Dallas

78229

University of Texas Health Science Center at San Antonio, University Hospital, San Antonio

80262

University of Colorado Hospital and Health Sciences Center, Denver

90033

USC University Hospital, Los Angeles

94143

University of California, San Fransisco Hospital, San Francisco

M5G 2N2

Toronto University Hospital - UHN, Toronto

H3A 1A1

Royal Victoria Hospital, Montreal

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00117689 - Evaluation of Thymoglobulin Induction and Reduced Doses of Calcineurin Inhibitors on Liver Transplant Rejection | Biotech Hunter | Biotech Hunter